TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05080855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified Millard technique vs Tennison-Randall technique
Description: evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified Millard technique vs Tennison-Randall technique
Description: evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
Study: NCT03784599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Tablet
Study: NCT00986401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium Chloride (Sanctura XR®)
Description: extended release, 60 mg, oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride (Glucophage®)
Description: immediate release, 500mg
Study: NCT03927235

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transbronchial Cryobiopsy
Description: Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy
Description: Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy
Description: Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy
Description: Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
Study: NCT05305222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) Infusion
Study: NCT00064259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT02373202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT03547739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home visits
Description: If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
Study: NCT01180426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797
Description: 120mg once daily oral for 48 weeks
Study: NCT02373202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bucillamine
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bucillamine
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizoribine
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizoribine
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT02392247

Intervention type: DEVICE
Intervention: Coagulation function
Description: Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
Study: NCT03108833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Prourokinase
Description: The drug is used for intravenous thrombolysis therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Prourokinase
Description: The drug is used for intravenous thrombolysis therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: The drug is used for intravenous thrombolysis therapy
Study: NCT01411228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase alfa for infusion every two weeks for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase alfa for infusion every two weeks for 24 months
Study: NCT03415191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
Study: NCT02393508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Human Red Blood Cells
Description: Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aged Human Red Blood Cells
Description: Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
Study: NCT00660998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5mg, 10mg or 20mg taken 1h before sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01989078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Adults and Children \>50 kg:~* Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~* Those with SBP \<100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children \<50 kg weight:~* Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved.
Study: NCT01244724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
Study: NCT01327105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVU
Description: Use of transvaginal ultrasound to determine location of micro-insert
Study: NCT01332474

Intervention type: DRUG
Intervention: BOTOX
Description: BOTOX
Study: NCT03547739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Self-testing
Description: Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
Study: NCT03688165

Intervention type: DEVICE
Intervention: Treadmill-based Robotic Gait Training
Description: All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
Study: NCT03932227

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardioskin
Description: Subjects will have a 24h recording with Cardioskin, next will be unequipped.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardioskin
Description: Subjects will have a 24h recording with Cardioskin, next will be unequipped.

Intervention type: DEVICE
Group type: OTHER
Intervention: Holter
Description: Subjects will have a 24h recording with Holter, next will be unequipped.

Intervention type: DEVICE
Group type: OTHER
Intervention: Holter
Description: Subjects will have a 24h recording with Holter, next will be unequipped.
Study: NCT03776383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic use feedback letter
Description: Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
Study: NCT03569774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-lung ventilation with low PEEP
Description: Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
Study: NCT02520674

Intervention type: OTHER
Group type: OTHER
Intervention: optic nerve head ophthalmoscopy
Description: Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
Study: NCT01338792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study: NCT02989194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS410 low dose
Description: Single intravenous fixed low dose of VIS410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS410 high dose
Description: Single intravenous fixed high dose of VIS410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous infusion of placebo
Study: NCT05533021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and Consultancy
Description: In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
Study: NCT02696473

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carrot

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carrot
Study: NCT03712150

Intervention type: DEVICE
Intervention: tdcs
Description: application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
Study: NCT02944123

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel 75 mg
Description: Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
Study: NCT01063608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-H1N1v Vaccine
Description: Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
Study: NCT04607304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABCA2 GIRMS
Description: Two systems (ABCA-C and ABCA-D) with run order randomized
Study: NCT01775579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage SR tablet 750 mg, Crestor tablet 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage SR tablet 750 mg, Crestor tablet 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage SR tablet 750 mg, Crestor tablet 20 mg
Study: NCT01405352

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: 25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: 25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month
Study: NCT02936310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Living With Stress
Description: The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
Study: NCT01516580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
Description: Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses.
Study: NCT02944123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg
Description: Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Description: Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
Study: NCT03074032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC1-0013B
Description: ONC1-0013B per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC1-0013B
Description: ONC1-0013B per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC1-0013B
Description: ONC1-0013B per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC1-0013B
Description: ONC1-0013B per os daily
Study: NCT01488656

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7-pill placebo dietary packed visually identical to active dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant, anti-inflammatory dietary supplement
Description: A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
Study: NCT03206060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTATATE
Description: Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-DOTATATE
Description: Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-FDG
Description: F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid solution
Description: AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
Study: NCT02624050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
Study: NCT04189146

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inner Engineering Intervention
Description: The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony.
Study: NCT04733183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onfekafusp alfa
Description: L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
Study: NCT04323787

Intervention type: OTHER
Intervention: observational
Description: No Intervention
Study: NCT01019343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QMAT
Description: The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill Test
Description: Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
Study: NCT01640951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 150 mg
Description: (1 injection per dose) and placebo to Secukinumab 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 150 mg
Description: (1 injection per dose) and placebo to Secukinumab 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300 mg
Description: Secukinumab 150 mg (2 injections per dose)
Study: NCT01019343

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Test
Description: Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Arm Intellistretch Device
Description: The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
Study: NCT01516580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
Description: LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
Study: NCT02312999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volulyte